|
|
|
10 Jun 2008 |
Halozyme Therapeutics Announces Phase I Clinical Trial Results Demonstrating that the Combination of Recombinant Human Hyaluronidase (rHuPH20) With Humulin R(R) and with Humalog(R) Yields Faster, More Physiologic Insulin Kinetics and Better Predictability
|
|
09 Jun 2008 |
Study Supports Possible Use Of Leukine(R) As A Potential Adjuvant Therapy For High-Risk Melanoma Patients
|
|
09 Jun 2008 |
Type 2 Diabetes Patients Taking Exenatide Once Weekly, a Phase 3 Investigational Diabetes Therapy, Showed Improvements in Glycemic Control, Weight
|
|
09 Jun 2008 |
XOMA 052 Demonstrates Anti-Inflammatory Effects in Diabetes Animal Studies; Data Presented At ADA
|
|
09 Jun 2008 |
Monotherapy BYETTA(R) (exenatide) Injection Study Results Presented at ADA 2008 Showed Adults with Type 2 Diabetes Experienced Improved Glycemic Control and Weight Loss
|
|
09 Jun 2008 |
New Diabetes Compound AVE0010 Showed Clear Dose Response Results With Once-A-Day Injection in Phase IIb Study
|
|
08 Jun 2008 |
Clinical study shows liraglutide provides statistically significantly better blood glucose control than exenatide
|
|
05 Jun 2008 |
Haemacure Achieves Major Milestone - Starts Processing Plasma in Its New Fractionation Facility
|
|
05 Jun 2008 |
BioMarin Announces Program for ERT for Treatment of MPS IVA - Morquio A Syndrome
|
|
05 Jun 2008 |
Pacgen Announces Positive Results from Phase IIb Dose-Ranging Trial of PAC-113
|
|
05 Jun 2008 |
Generex Biotechnology Commences Patient Dosing For Pivotal Phase III Trial of Generex Oral-lyn
|
|
05 Jun 2008 |
SemBioSys Demonstrates Functionality of its Safflower Produced Apo AI(Milano)
|
|
04 Jun 2008 |
Auxilium Pharmaceuticals, Inc. Announces XIAFLEX(TM) Meets Primary Endpoint With Statistical Significance (p
|
|
04 Jun 2008 |
The GI Company Reports Significant Reduction In Occurrence Of Oral Mucositis In Phase II Study Presented At ASCO
|
|
04 Jun 2008 |
Haemacure Achieves Major Milestone - Starts Processing Plasma in Its New Fractionation Facility
|
|
03 Jun 2008 |
Mentor Announces Completion of Enrollment in Phase I Trial for Botulinum Toxin Type A in Patients with Cervical Dystonia
|
|
02 Jun 2008 |
Novo Nordisk and Neose announce completion of initial phase 1 clinical trial of NN7128 (long-acting factor VIIa) (2 Jun 2008)
|
|
02 Jun 2008 |
Multiple Clinical Trials of VELCADE(R) (Bortezomib) for Injection Based Therapies Demonstrate High Complete Remission Rates in Patients with Newly Diagnosed Multiple Myeloma
|
|
30 May 2008 |
TransMolecular Initiates Phase 1 Clinical Trial for Unlabeled TM601 in Recurrent Malignant Glioma
|
|
30 May 2008 |
Boehringer Ingelheim gets first approval within EU for Actilyse(R) 2mg to treat catheter dysfunction caused by thrombotic occlusion
|
|
29 May 2008 |
Alfacell Corporation Announces Preliminary Results From ONCONASE(R) Phase IIIb Clinical Trial
|
|
28 May 2008 |
Stem Cell Therapeutics Corp. Announces Enrollment of the First Patient in its REGENESIS Phase IIb Stroke Trial
|
|
27 May 2008 |
ZymoGenetics Announces FDA Approval of RECOTHROM(TM) 20,000-IU Vial Size and Co-Packaging with Spray Kit
|
|
27 May 2008 |
Biovitrum and Syntonix Dose First Hemophilia B Patient in Clinical Trial of a Novel Factor IXFc Treatment
|
|
26 May 2008 |
Extavia(R) approved in European Union for treatment of multiple sclerosis, first in planned portfolio of therapies from Novartis
|
|
23 May 2008 |
Novo Nordisk files for regulatory approval of liraglutide in both the US and Europe
|
|
23 May 2008 |
Allon completes dosing in Phase II cognitive impairment trial
|
|
23 May 2008 |
ThromboGenics Presents Further Results of the Vitreomacular Traction Trial (MIVI IIT) at the Euretina Annual Meeting in Vienna
|
|
21 May 2008 |
Osiris Therapeutics Initiates Phase II Clinical Trial Evaluating Prochymal(TM) for Chronic Obstructive Pulmonary Disease
|
|
21 May 2008 |
Paion's Anticoagulant Solulin Achieves Proof Of Concept For Mode of Action in Phase I
|
|
20 May 2008 |
Halozyme Therapeutics Presents Pre-Clinical Studies on Dermal Remodeling With HTI-501, a Lysosomal Proteinase
|
|
20 May 2008 |
BioMarin Initiates Phase 1 Clinical Study of PEG-PAL in PKUBioMarin Initiates Phase 1 Clinical Study of PEG-PAL in PKU
|
|
20 May 2008 |
Palatin Technologies initiates phase 2 hypertension clinical study with PL-3394
|
|
19 May 2008 |
Ipsen and Medicis Announce Acceptance of Reloxin BLA in Aesthetics by FDA
|
|
19 May 2008 |
Sangart, Inc. Completes Enrollment In Second Phase III Study of Hemospan, A Novel Oxygen Transport Agent
|
|
19 May 2008 |
New Data Support High Complete Remission Rates With VELCADE(R) (Bortezomib) For Injection Based Therapies In Patients With Newly Diagnosed Multiple Myeloma
|
|
19 May 2008 |
Gloucester Pharmaceuticals Announces Positive Results from Phase 2b Registration Trial of Romidepsin in Refractory CTCL
|
|
16 May 2008 |
The GI Company Reports Significant Reduction in Occurrence of Oral Mucositis in Phase II Study; Abstract Posted Online at ASCO.org
|
|
16 May 2008 |
ZymoGenetics Announces Publication of Five IL-21 ASCO Abstracts
|
|
15 May 2008 |
Ambrilia Reports Positive Final Phase III Results for its Octreotide Formulation C2L
|
|
15 May 2008 |
Protox Doses First Patient In Phase 2 BPH Clinical Trial
|
|
14 May 2008 |
Ęterna Zentaris Announces First Patient Dosing for Safety Trial of Phase 3 Program with Cetrorelix in Benign Prostatic Hyperplasia
|
|
14 May 2008 |
Platin Technologies announces new strategis objectives and reports third quater 2008 financial results
|
|
12 May 2008 |
FDA Approves New Formulation of Coagulation Therapy
|
|
12 May 2008 |
Theratechnologies and PDC Biotech GmbH sign license agreement for family of peptides for Preterm Labour and Primary Dysmenorrhea programs
|
|
12 May 2008 |
Alseres Pharmaceuticals Announces 12 Month Interim Results from the Phase I/IIa Cethrin(R) Clinical Trial in Acute Spinal Cord Injury
|
|
12 May 2008 |
Affymax and Takeda Announce Long-Term Hematide Safety and Effectiveness Data from Phase 2 Clinical Trials in Chronic Kidney Disease Patients with Anemia
|
|
12 May 2008 |
Velcura Therapeutics, Inc. Reports Successful Phase 1 Clinical Trial of Novel Bone Disease Therapy
|
|
08 May 2008 |
OrthoLogic Announces Positive Safety Data for Initial AZX100 Phase 1 Human Clinical Trial in Dermal/Hypertrophic Scarring
|
|
08 May 2008 |
LFB Biotechnologies and GTC Biotherapeutics to collaborate on rhAAT program
|
| |
|
Results 101 - 150 of 1318 |
